Overstimulation of the NMDA receptors by glutamate is implicated in neurodegenerative disorders, including Alzheimer’s disease (AD) 1
The NMDA receptor antagonist memantine is approved for the treatment of moderate/severe AD alone or in combination with cholinesterase inhibitors2-4
Memantine has been shown to reduce clinical deterioration in moderate/severe AD1
Furthermore, treatment with memantine has been shown to reduce symptoms such as agitation, aggression, irritability,and appetite disturbances5
Acess our Slide Deck on treatment principles of AD and learn more about pharmacological treatment of AD.
Related content
Brain drug delivery systems, allied with their characteristics for overcoming the blood-brain barrier (BBB).
The use of a single treatment in heterogeneous populations has proved problematic in clinical trials undertaken in patients with neurodegenerative diseases.